306 related articles for article (PubMed ID: 9831269)
21. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2002 May; 16(5):881-6. PubMed ID: 11966495
[TBL] [Abstract][Full Text] [Related]
22. Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
Croom KF; Scott LJ
Drugs; 2005; 65(15):2129-35; discussion 2136-7. PubMed ID: 16225368
[TBL] [Abstract][Full Text] [Related]
23. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Nzeako UC; Murray JA
Aliment Pharmacol Ther; 2002 Jul; 16(7):1309-16. PubMed ID: 12144581
[TBL] [Abstract][Full Text] [Related]
24. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
25. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease.
Robinson M; Maton PN; Rodriguez S; Greenwood B; Humphries TJ
Aliment Pharmacol Ther; 1997 Oct; 11(5):973-80. PubMed ID: 9354209
[TBL] [Abstract][Full Text] [Related]
26. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
Fiedorek S; Tolia V; Gold BD; Huang B; Stolle J; Lee C; Gremse D
J Pediatr Gastroenterol Nutr; 2005 Mar; 40(3):319-27. PubMed ID: 15735486
[TBL] [Abstract][Full Text] [Related]
28. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Stolte M; Vieth M; Schmitz JM; Alexandridis T; Seifert E
Scand J Gastroenterol; 2000 Nov; 35(11):1125-30. PubMed ID: 11145281
[TBL] [Abstract][Full Text] [Related]
29. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group.
Bardhan KD; Hawkey CJ; Long RG; Morgan AG; Wormsley KG; Moules IK; Brocklebank D
Aliment Pharmacol Ther; 1995 Apr; 9(2):145-51. PubMed ID: 7605854
[TBL] [Abstract][Full Text] [Related]
30. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Frazzoni M; De Micheli E; Grisendi A; Savarino V
Aliment Pharmacol Ther; 2003 Jan; 17(2):235-41. PubMed ID: 12534408
[TBL] [Abstract][Full Text] [Related]
31. Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
Katz PO; Hatlebakk JG; Castell DO
Aliment Pharmacol Ther; 2000 Jun; 14(6):709-14. PubMed ID: 10848653
[TBL] [Abstract][Full Text] [Related]
32. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Miner P; Katz PO; Chen Y; Sostek M
Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
[TBL] [Abstract][Full Text] [Related]
33. Esomeprazole: a review of its use in the management of acid-related disorders.
Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
[TBL] [Abstract][Full Text] [Related]
34. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial.
Mulder CJ; Westerveld BD; Smit JM; Oudkerk Pool M; Otten MH; Tan TG; van Milligen de Wit AW; de Groot GH;
Eur J Gastroenterol Hepatol; 2002 Jun; 14(6):649-56. PubMed ID: 12072599
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease.
Havelund T; Aalykke C; Rasmussen L
Eur J Gastroenterol Hepatol; 1997 May; 9(5):509-14. PubMed ID: 9187886
[TBL] [Abstract][Full Text] [Related]
36. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole.
Johnsson F; Moum B; Vilien M; Grove O; Simren M; Thoring M
Scand J Gastroenterol; 2002 Jun; 37(6):642-7. PubMed ID: 12126240
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
38. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies.
Berstad A; Hatlebakk JG
Aliment Pharmacol Ther; 1993; 7 Suppl 1():34-6, discussion 61-6. PubMed ID: 8490077
[TBL] [Abstract][Full Text] [Related]
39. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
Galmiche JP; Barthelemy P; Hamelin B
Aliment Pharmacol Ther; 1997 Aug; 11(4):765-73. PubMed ID: 9305487
[TBL] [Abstract][Full Text] [Related]
40. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Robinson M; Sahba B; Avner D; Jhala N; Greski-Rose PA; Jennings DE
Aliment Pharmacol Ther; 1995 Feb; 9(1):25-31. PubMed ID: 7766740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
